Illumina provides an innovative portfolio of next-generation sequencing (NGS) systems, products, and services for the drug development pipeline. With solutions to inform the drug development process, you can confidently choose us as a partner from discovery through companion diagnostics development.
NGS approaches can generate multiple levels of genomic data essential for drug development, from genomic modifications to transcriptome profiling and quantification, epigenetic modifications, and more.
We are uniquely positioned to deliver products and services to support pharmaceutical development with the largest install base of next-generation sequencing (NGS) instrumentation.
Approximately 90 percent of all sequencing data produced today has been generated using Illumina technologies*. Reference and service labs are installing our instruments in increasing numbers to perform a wide variety of applications.
* Data calculations on file. Illumina, Inc. 2017
The Illumina portfolio of solutions informs various stages of the drug development process.
Click on the below to view methods and products supporting drug development.
Take a comprehensive view of the genomic variation linked to a pathway.
Whole-Exome SequencingExplore genomic variation in a more cost-effective way.
RNA SequencingCharacterize expression by sequencing individual targets to the entire transcriptome.
Targeted Cancer SequencingTake a deeper view to confirm genomic variation of interest with custom or fixed panels.
TruSight Oncology 500 Product FamilyEnabling comprehensive genomic profiling from both blood and tissue samples.
Cancer Immunotherapy ResearchNGS methods enable efficient, broad, and deep assessment of tumors and their microenvironment.
Learn how to use RNA-Seq to identify novel RNA-based drug response biomarkers.
EpigeneticsFind NGS and array tools to study epigenetic modifications and their impact on gene regulation.
Sequencing SystemsFind the sequencer that best fits your scale of study.
Microarray SolutionsA complete range of tools and services for every need.
Bioinformatics ToolsInformatics tools to guide you from experimental design to data interpretation and reporting.
Service ProvidersFind a service provider through our Propel program to support your genomics needs.
Take a deeper view to confirm genomic variation of interest with custom or fixed panels. Detect single-nucleotide variants (SNVs), amplifications, and fusions that contribute to solid tumor progression with TruSight Tumor 170.
TruSight Oncology 500 Product FamilyEnabling comprehensive genomic profiling from both blood and tissue samples.
Cancer RNA SequencingConfirm expression in transcripts of interest with targeted panels and access hard-to-analyze FFPE samples. Also leverage RNA-Seq to discover and profile RNA-based drug response biomarkers.
Immunotherapy ResearchNGS methods enable efficient, broad, and deep assessment of tumors and their microenvironment
Find the sequencer that best fits your scale of study.
InformaticsBioinformatics tools guide you from experimental design to data interpretation and reporting.
Service ProvidersFind a service provider through our Propel program to support your genomics needs.
Take a deeper view to confirm genomic variation of interest with custom or fixed panels. Detect single-nucleotide variants (SNVs), amplifications, and fusions that contribute to solid tumor progression with TruSight Tumor 170.
TruSight Oncology 500 Product FamilyEnabling comprehensive genomic profiling from both blood and tissue samples.
Cancer RNA SequencingConfirm expression in transcripts of interest with targeted panels and access hard-to-analyze FFPE samples. Also leverage RNA-Seq to discover and profile drug response RNA biomarkers.
Immunotherapy ResearchNGS methods enable efficient, broad, and deep assessment of tumors and their microenvironment
Find the sequencer that best fits your scale of study.
InformaticsBioinformatics tools guide you from experimental design to data interpretation and reporting.
Service ProvidersFind a service provider through our Propel program to support your genomics needs.
Explore our unique, multi-analyte approach to co-development.
Targeted Cancer SequencingTake a deeper view to confirm genomic variation of interest with custom or fixed panels. Detect single-nucleotide variants (SNVs), amplifications, and fusions that contribute to solid tumor progression with TruSight Tumor 170.
TruSight Oncology 500 Product FamilyEnabling comprehensive genomic profiling from both blood and tissue samples.
Cancer RNA SequencingConfirm expression in transcripts of interest with targeted panels and access hard-to-analyze FFPE samples.
Immunotherapy ResearchNGS methods enable efficient, broad, and deep assessment of tumors and their microenvironment.
Find the sequencer that best fits your scale of study.
Companion Diagnostics DevelopmentExplore our unique, multi-analyte approach to co-development.
High-Throughput Genotyping Research ToolsGain meaningful insights from complex populations.
InformaticsBioinformatics tools guide you from experimental design to data interpretation and reporting.
Service ProvidersFind a service provider through our Propel program to support your genomics needs.
Explore our unique, multi-analyte approach to co-development.
MiSeqDx InstrumentDiscover the first FDA-cleared next-generation sequencing system.
NextSeq550Dx InstrumentExplore the next level in diagnostic power for the clinical lab.
Gain meaningful insights from complex populations.
Service ProvidersFind a service provider through our Propel program to support your genomics needs.
Integrating imaging, multiomic technologies, and big data uncovers novel diagnostic and therapeutic targets for common chronic diseases.
Read InterviewResearchers utilize transcriptomics to uncover multiple drug-susceptible tumorigenic pathways.
Read InterviewWhole-genome shotgun sequencing and transcriptomics provide researchers and pharmaceutical companies with data to refine drug discovery and development.
Read InterviewNGS-based methods allow cancer researchers to detect rare somatic variants, tumor subclones, and circulating DNA fragments. Learn more about cancer genomics.
From metagenomics and microbiome studies to infectious disease surveillance, NGS can help researchers gain genetic insight into bacteria and viruses. Learn more about microbial genomics.
Sequencing is introducing new avenues for understanding autoimmune diseases, atherosclerosis, neurological diseases, and psychiatric disorders on a molecular level. Learn more about complex disease genomics.
NGS can help scientists uncover genetic variants associated with rare and undiagnosed disorders. Learn more about rare disease genomics.
Read how Merck Serono uses NGS for cell line stability testing and biosafety monitoring.
Access resources to explore NGS-based biomarker discovery and profiling.
Polygenic risk scores represent the total number of genetic variants that an individual has to assess their heritable risk of developing a particular disease.
Regeneron discusses their latest work and overall mission to explore new variations in genomes that can help explain disease.